Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Discovery chemistry services provider Chemical Diversity has entered into a collaborative agreement with the University of Maryland Greenebaum Cancer Center to focus on pharmaceutical discovery for the treatment of breast cancer.
Subscribe to our email newsletter
Under the terms of the agreement, the University of Maryland Greenebaum Cancer Center (UMGCC) will be granted access to the diverse libraries designed by Chemical Diversity (ChemDiv). In addition, ChemDiv will provide medicinal chemistry services to accelerate the discovery and lead optimization efforts at UMGCC.
UMGCC is a premier cancer research and treatment center devoted to providing cutting-edge therapies and individualized care for cancer patients.
“Access to high-quality compound libraries and medicinal chemistry services from Chemical Diversity will improve our chances of finding high affinity compounds that selectively target breast cancer cells with defined genetic alterations,” said Dr Kurtis Bachman, a UMGCC researcher and an assistant professor of medicine at the University of Maryland School of Medicine.
Dr Bachman receives some funding for his research from the Maryland Cigarette Restitution Fund Program, which channels monies from a legal settlement with large tobacco companies into cancer research, education and treatment.